GU Cancers 2024 | SPPORT: ADT and salvage radiotherapy in prostate cancer

Alan Dal Pra, MD, University of Miami, Miami, FL, gives an overview of findings from the Phase III NRG Oncology/RTOG 0534 SPPORT trial (NCT00567580), which assessed prostate bed radiotherapy (PBRT) alone or with either androgen deprivation therapy (ADT) or pelvic lymph node radiotherapy (PLNRT). Freedom from progression (FFP) was met in the trial, and patients who have a recovery in testosterone levels had similar outcomes compared to the rest of the cohort. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.